Successful chimeric antigen receptor (CAR) T-cell treatment in aggressive lymphoma despite coronavirus disease 2019 (CoVID-19) and prolonged severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) replication
- In patients with compromised immune function, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (CoVID-19) impose particular challenges. Especially in hematological malignancies, including lymphoma, the demands by this novel virus disease are further enhanced during sophisticated treatments, such as chimeric antigen receptor (CAR) T-cell therapy. Here, we present the first case of a patient with refractory diffuse-large B-cell lymphoma, who underwent CAR T-cell treatment in the context of SARS-CoV-2. Irrespective of prolonged and active SARS-CoV-2 infection, T cells were successfully isolated by apheresis and processed to anti-CD19 CAR T cells (axicabtagene-ciloleucel). In light of the aggressive lymphoma course, lymphodepleting chemotherapy and CAR-T cells were administered in early recovery after oxygen-dependent CoVID-19 pneumonia. Except for moderate cytokine release, this cellular immunotherapy was well tolerated. Notably, there is no deterioration of the SARS-CoV-2 infection; however, complete lymphoma response and full clinical recovery were observed. In conclusion, CAR T-cell treatment in aggressive lymphoma in the setting of SARS-CoV-2 infection is feasible and may offer significant therapeutic activity in refractory disease.
Author: | Verena Nilius-EliliwiORCiDGND, Thomas MikaORCiDGND, Alexander BaraniskinGND, Max WünnenbergGND, Marina MaslovaGND, Christian BoyGND, Susanne Klein-ScoryORCiDGND, Roland SchroersORCiDGND, Deepak VangalaORCiDGND |
---|---|
URN: | urn:nbn:de:hbz:294-87617 |
DOI: | https://doi.org/10.3389/fonc.2021.706431 |
Parent Title (English): | Frontiers in oncology |
Subtitle (English): | Case report |
Publisher: | Frontiers |
Place of publication: | Lausanne |
Document Type: | Article |
Language: | English |
Date of Publication (online): | 2022/03/24 |
Date of first Publication: | 2021/07/14 |
Publishing Institution: | Ruhr-Universität Bochum, Universitätsbibliothek |
Tag: | Open Access Fonds CoVID-19; SARS-CoV-2; chimeric antigen receptor T-cells; diffuse large B-cell lymphoma; pneumonia |
Volume: | 11 |
Issue: | Article 706431 |
First Page: | 706431-1 |
Last Page: | 706431-7 |
Note: | Article Processing Charge funded by the Open Access Publication Fund of Ruhr-Universität Bochum. |
Institutes/Facilities: | Knappschaftskrankenhaus Bochum, Medizinische Klinik, Hämatologie / Onkologie |
Dewey Decimal Classification: | Technik, Medizin, angewandte Wissenschaften / Medizin, Gesundheit |
open_access (DINI-Set): | open_access |
Licence (English): | Creative Commons - CC BY 4.0 - Attribution 4.0 International |